UsAgainstAlzehimer's: Power of Us

Get to know UsAgainstAlzheimer’s, what we’ve accomplished, and where we’re headed through our powerful video introduction.

Alzheimer's Patients and Caregivers Celebrate FDA Approval of Lecanemab

CMS and Lecanemab’s manufacturers must work together to provide access to patients.

Congress Delivers Major Wins for Alzheimer’s Patients

Alzheimer’s patients, caregivers, and advocates secured major wins in the end-of-year budget package passed by Congress today. In addition to a $226 million increase in research funding, the bill includes key priorities advocated for by UsAgainstAlzheimer’s.

Lecanemab Trial Data Gives Hope to Alzheimer’s Community

Promising new data released today indicate that help could soon be on the way for people living in the early stages of Alzheimer’s.

The Brain Health Academy

Free, evidence-based courses to equip healthcare and wellness providers with the knowledge and resources to help people reduce the risk of dementia and Alzheimer’s.

Say Hello to BrainGuide

Our platform BrainGuide™ empowers people of all ages and communities to understand and take action on brain health and Alzheimer's disease.

UsAgainstAlzehimer's: Power of Us

Alzheimer's Patients and Caregivers Celebrate FDA Approval of Lecanemab

Congress Delivers Major Wins for Alzheimer’s Patients

Lecanemab Trial Data Gives Hope to Alzheimer’s Community

The Brain Health Academy

Say Hello to BrainGuide

UsAgainstAlzheimer's: Working to End Alzheimer's Disease  

The Alzheimer’s pandemic is one of the most significant health and social economic crises of this generation. It is a national and global emergency that has a devastating health, social and economic toll on millions of people living with this disease, their families and caregivers.

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. Since our founding in 2010, we have taken on the toughest problems in the fight to end Alzheimer’s. Our work is driven by the urgency to find effective treatments and the prevention steps needed to reach the time where no one is lost to Alzheimer’s.

We bring all of “Us” together to:

In the past decade, progress has been made, with more hope on the horizon now than ever before.

But every day of delay is another day lost to the millions of people affected by this devastating disease. If nothing changes, by 2050, 14 million Americans will be living with Alzheimer’s at an annual cost of more than $1 trillion. The time to act is now.

Recent News and Blog Posts

  • January 20, 2023

    UsAgainstAlzheimer’s Statement on FDA Complete Response Letter for Donanemab

    Washington, D.C. (January 19, 2023) – UsAgainstAlzheimer’s chief operating officer Russ Paulsen issued...

    Read more
  • January 06, 2023

    Alzheimer's Patients and Caregivers Celebrate FDA Approval of Lecanemab

    Washington, D.C. (January 6, 2022) – Millions of Americans living with Alzheimer’s...

    Read more
  • 30 Years On, Are We Winning the Fight Against Alzheimer’s?

    Lecanemab, Donanemab, Drug-Free Strategies Emerge as New Weapons Against Dementia

    By Suzanne Leigh...

    Read more
  • December 23, 2022

    Congress Delivers Major Wins for Alzheimer’s Patients

     Alzheimer’s patients, caregivers, and advocates secured major wins in the end-of-year budget...

    Read more
  • A-LIST Pulse of the Community Vol 14, December 2022

    The mission of the A-LIST is to use survey results to make...

    Read more
  • December 01, 2022

    Gantenerumab Trial Results Reinforce Need for Continued Research and Treatment-Specific Regulation

    Yesterday, at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, researchers ...

    Read more

Reports

  • Resources

    A-LIST Pulse of the Community – November 2022

  • Resources
    Us Against Alzheimer's 2021 Annual Report

    2021 Annual Report

    With breakthroughs in treatment, a remarkable step forward in prevention, and a new initiative to raise public awareness of the importance of brain health, many efforts were led by UsAgainstAlzheimer’s...

  • Resources
    A-List 2017-2022 surveys

    A-List What Matters Most Surveys

    A-List 2017-2022 surveys, updated July 2022